COMBINATION OF ET-743 WITH 5-FLUOROURACIL PRO-DRUGS FOR THE TREATMENT OF CANCER
Publication number: HR20080598 (T3)
Publication date: 2009-01-31
Inventor(s): RYBAK MARY ELLEN [US]
Applicant(s): PHARMA MAR [ES]
Classification:
- international: A61K31/498; A61K31/513; A61K31/7068; A61P35/00; A61K31/498; A61K31/513; A61K31/7042; A61P35/00
- European: A61K31/498; A61K31/513; A61K31/7068
Application number: HR20080000598T 20081202
Priority number(s): US20030519690P 20031113; WO2004GB50026 20041115
Abstract not available for HR 20080598 (T3)
Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of capecitabine is administered in combination with ET-743 in a dose range between 0.75 and 1.4 mg/m<2> for Et-743. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with capecitabine in a dose range between 1500 to 2500 mg/m/day for capecitabine.